Northwire Canada EditionThursday, July 23, 2026
Sign inSubscribe
Northwire
⌕
VZZ 0.180 +2.9% BMR 0.145 +3.6% NVO 0.055 −8.3% PMET 4.47 +2.0% CTG 0.125 +13.6% AVU 0.040 +0.0% SGML 14.32 −3.1% WRLG 0.720 +1.4% CAN 0.065 +8.3% ABRA 15.63 +1.6% LSTR 0.060 +0.0% OLA 13.10 +2.5% EQX 13.15 +2.7% SRA 0.780 +0.0% UTWO 0.390 −13.3% IVN 10.64 −1.2% VZZ 0.180 +2.9% BMR 0.145 +3.6% NVO 0.055 −8.3% PMET 4.47 +2.0% CTG 0.125 +13.6% AVU 0.040 +0.0% SGML 14.32 −3.1% WRLG 0.720 +1.4% CAN 0.065 +8.3% ABRA 15.63 +1.6% LSTR 0.060 +0.0% OLA 13.10 +2.5% EQX 13.15 +2.7% SRA 0.780 +0.0% UTWO 0.390 −13.3% IVN 10.64 −1.2%
Financings

Quantum Biopharma licensee to hold webinar Sept. 16

By The Northwire Desk — AI Analysis Sep 12, 2025 · 16:32 QNTM · 23.80 Quantum Biopharma Ltd
QNTM · Price

Executive Summary

  • Quantum Biopharma Ltd. licensee, Unbuzzd Wellness Inc., is hosting an investor webinar on September 16, 2025, to discuss its Regulation D 506(c) investment opportunity.
  • Unbuzzd Wellness aims to raise up to $5 million (U.S.) to support aggressive expansion plans and a potential initial public offering (IPO).
  • Quantum Biopharma retains a 20.10% ownership stake in Unbuzzd Wellness and is entitled to 7% of sales royalties until $250 million is reached, after which the rate drops to 3% in perpetuity.

Key Details

  • Webinar Details: Hosted by Unbuzzd Wellness Inc. on Tuesday, Sept. 16, 2025, at 1:30 p.m. PT (4:30 p.m. EST).
  • Participants: CEO John Duffy, adviser Jason Sawyer, medical director Dr. Eric Hoskins, and board co-chair Gerry David.
  • Financing Opportunity: Regulation D 506(c) offering with expected gross proceeds of up to $5 million (U.S.).
  • Use of Proceeds: Support aggressive expansion plans and possible initial public offering.
  • Dilution: Quantum Biopharma shareholders will not be diluted by this specific offering.
  • Clinical Trial Results (Double-blind, placebo-controlled):
    • Alcohol Metabolism: Unbuzzd reduced blood alcohol concentration (BAC) more than 40% faster within 30 minutes compared to control subjects.
    • Alertness: Statistically significant improvement in alertness and fewer cognitive errors within 30 minutes.
    • Physiologic Changes: Statistically significant stabilization of heart rate elevation and blood pressure drops associated with intoxication.
    • Hangover Relief: Statistically significant reduction in hangover symptoms, including a 67% reduction in headache severity at four hours and eight hours post-consumption.
    • Safety: No reported adverse side effects; well-tolerated by all participants.
  • Quantum Biopharma Stake & Royalties:
    • Quantum Biopharma owns 20.10% of Unbuzzd Wellness (as of June 30, 2025).
    • Royalty structure: 7% of Unbuzzd sales until $250 million is paid to Quantum Biopharma.
    • Post-$250 million threshold: Royalty drops to 3% in perpetuity.
    • Quantum Biopharma retains 100% of rights to develop similar products for pharmaceutical/medical uses.

Notable Quotes

  • John Duffy, CEO of Unbuzzd Wellness: "We look forward to this opportunity to engage and inform current and potential investors about the rapidly expanding global market for Unbuzzd. We will review the science behind how it works and discuss results from our double-blind, placebo-controlled clinical study. We will also discuss the current opportunity to invest in our Regulation D 506(c) offering, where we expect to raise up to $5-million (U.S.) to support our aggressive expansion plans and possible initial public offering."
Read the original news release →

More from Quantum Biopharma Ltd

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other